Answers are grounded in this paper and cite their sources.
Levels of pSyk in peripheral blood B cells were significantly elevated in patients with RA, and these patients also exhibited strong positivity for ACPAs. These data suggest that abatacept seems to inhibit the phosphorylation of Syk in B cells, as well as the development of Tfh cells, thus highlighting the relevance of B cell-T cell interactions as a potential target of abatacept therapy in RA.
No takes yet. Share an insight, caveat, or question.
Iwata et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: